Кращі подкасти про Labiotech (2024)

1
The biotech investment landscape in 2024 28:32

7d ago28:32

28:32

RTW is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. The company invests in both public and private companies across their entire life cycle, with a focus on those addressing next-generation gene and RNA therapies, rare diseases, targeted oncological, cardi…

1
Redefining chronic pain treatment 35:42

14d ago35:42

35:42

Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologies to better understand the progression of neurological diseases like chronic pain. The Doloromics pipeline is…

1
Colossal aims to bring back mammoth by 2028 38:24

21d ago38:24

38:24

Based in Austin, Texas, biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems. Its mission is to use CRISPR technology to bring back extinct animals, such as the mammoth, the thylacine, and the dodo. Since DNA was recovered in 2021 from mammoths frozen…

1
New treatments being developed for schizophrenia 25:31

1M ago25:31

25:31

It would appear that 2024 is shaping up to be a big year for the development of treatments for schizophrenia, with several clinical trials under way. Recently, Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) announced a global collaboration and exclusive option-to-license agreement. This is to develop and commercialize Sosei Hepta…

1
Reformulating psychedelics for neurodegenerative diseases 41:37

1M ago41:37

41:37

There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient. Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics …

1
How AI immune system mapping can boost drug discovery 28:46

2M ago28:46

28:46

Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than ever before. In this wee…

1
Is Tome writing the final chapter in genomic medicine? 33:11

2M ago33:11

33:11

Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding. The company has developed a new approach to gene editing, programmable genomic integration (PGI), which it says represents the final chapter in genomic medicines. We discussed the company’s formation and approach with the CEO and president of Tome, …

1
Transforming treatments for epilepsy 41:27

2M ago41:27

41:27

After decades of lagging nearly many other disease areas, neurology is finally seeing signs of significant innovation. One of the biggest reasons it’s trailed behind has been the difficulty in teasing out complex neurobiology – an understanding necessary to design novel medicines. Rapport Therapeutics is playing a significant role in turning the ti…

1
How does AI assist drug discovery? 38:26

2M ago38:26

38:26

Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time. A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" canc…

1
Biosimilars and what’s new in cell and gene therapies 37:17

3M ago37:17

37:17

This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and what’s new at Advanced Therapies Week. 00:40-02:30: About Cardinal Health 02:30-05:12: What is Cardinal Health’s …

1
BioSenic developing severe knee osteoarthritis treatment 31:43

3M ago31:43

31:43

BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria. The post hoc analysis of a phase 3 study found that a single injection of JT…

1
Boosting fertility by changing the vaginal microbiome 32:38

3M ago32:38

32:38

Freya Biosciences is a clinical-stage biotech company dedicated to reimagining women's health and redefining fertility for those previously deprived of options. With a focus on microbial immunotherapies, Freya addresses immune drivers underlying a range of reproductive health conditions. The company recently received $38 million Series A financing …

1
Epic Bio - gene editing without cutting DNA 32:43

3M ago32:43

32:43

Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. This week, we discuss epigenetic editing, why it’s reversibl…

1
Could natural killer cells transform Alzheimer’s treatment? 28:14

3M ago28:14

28:14

A US company, with its origins in South Korea, is using natural killer (NK) cells to treat Alzheimer’s disease, with remarkable results. This week, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer’s treatment landscape. 00:58-02:55: About NKGen Biotech 02:56-05:39: Why is Alzhei…

1
Gene editing in the microbiome to treat acne 29:02

4M ago29:02

29:02

Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome. Its first target is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population. This week, we talk to Xavier Duportet, CEO of Eligo Bioscience, as the company looks …

1
Tackling challenging diseases with vaccines 25:47

4M ago25:47

25:47

Vaxxinity, Inc. is a U.S.-based biotechnology company looking to develop vaccines for several hard-to-treat diseases such as Alzheimer’s and Parkinson’s. The company is pioneering a new class of medicines through its proprietary technology platform, which has enabled the innovation of novel synthetic peptide immunotherapy candidates to bring the ef…

1
Using worms to treat diseases 21:37

5M ago21:37

21:37

Is there a connection between worms being eradicated from the gut in the early 20th Century and an increase in allergies and autoimmune disease? This week, we have a conversation with Holoclara CEO Andrea Choe, who not only believes there is a connection, but also sees secretions from worms as a way to tackle such diseases. 01:31-06:05: About Holoc…

1
Ipsen advances liver disease treatment 21:47

5M ago21:47

21:47

Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen. On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease. 00:56-00:49: Background information 01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver…

1
New class of small molecule therapeutics introduced 26:35

5M ago26:35

26:35

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience. 00:45-01:06: About Gate Bioscience 01:06-02:09: What are disease-causing extracellular proteins? 02:09-04:44: How have diseases caused by extracellular proteins been treated in the past? 04:4…

1
How to make vaccines affordable 40:36

5M ago40:36

40:36

Among other things, UK-headquartered company Phenotypeca has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries to reduce the costs of vaccines. The company’s CEO, Johnny Cordiner, and research and development director, Professor Ed Louis, tell us about the work, as well as the company and i…

1
Mending a broken heart with biotech 29:10

6M ago29:10

29:10

French company CellProthera has seen some remarkable results treating people who have had a heart attack. On this week’s podcast, the company’s CEO Matthieu de Kalbermatten tells us how it works. 01:00-03:29: About CellProthera 03:30-06:30: What are ProtheraCytes? 06:30-09:02: Is this a cure? 09:02-10:24: Is prevention the best option? 10:25-11:49:…

1
How quantum computing can accelerate drug discovery 28:45

6M ago28:45

28:45

On today’s podcast, Jean-Philip Piquemal, the chief scientific officer and co-founder of Qubit Pharmaceuticals, explains how the company’s Atlas platform is leading the way to more effective and safer drugs. 00:54-01:52: The history of Qubit Pharmaceuticals 01:52-04:04: What is the Atlas software? 04:04-05:18: Failing quickly is the key 05:19-06:53…

1
Beyond Biotech podcast 69 – improving access to cell and gene therapy 37:06

6M ago37:06

37:06

This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT). Ori has developed a proprietary, full stack manufacturing platform that …

1
Beyond Biotech podcast 68 – rejuvenation with stem cells 29:43

6M ago29:43

29:43

This week, our guest on the podcast is Mark Kotter, founder of newly-created company clock.bio. clock.bio, a sister company to bit.bio, which Kotter also founded and is the CEO of, aims to extend and improve quality of life by reversing the harmful effects of time in our cells, harnessing the regenerative capabilities of human pluripotent stem cell…

1
Beyond Biotech podcast 67 – natural killer cells 28:55

7M ago28:55

28:55

This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoi…

1
Beyond Biotech podcast 66 – treating rare diseases with tRNA 32:08

7M ago32:08

32:08

Compared to the smallest mRNA molecule, which is 300 nucleotides long, the largest transfer RNAs (tRNA) is less than a third of the size at 76 nucleotides. Scientists at Alltrna are harnessing the unique biology of tRNAs to engineer a single tRNA medicine that could treat thousands of rare diseases that share the same genetic mutation. This year, A…

1
Beyond Biotech podcast 65 – Disease X and pandemic preparedness 43:11

7M ago43:11

43:11

Disease X, a concept shrouded in mystery, represents the unknown pathogens that could unleash future epidemics or pandemics. In the wake of recent global health crises, our understanding of the profound impact of those pandemics has deepened. On this week’s podcast, we have a conversation with Hamilton Bennett, who led Moderna’s mRNA-1273 COVID-19 …

1
Beyond Biotech podcast 64 – Precision immuno-oncology therapies 38:31

7M ago38:31

38:31

Despite the huge commercial success of PD-1 inhibitors and widespread use of checkpoint inhibitors such as anti-PD-1 or anti-CTLA4, 70 to 80% of patients still experience limited or no response to existing therapies. In response to this critical challenge, Portage Biotech is on a mission to expand the number of patients who derive long-term benefit…

1
Beyond Biotech podcast 63 – Tackling cancer with STRIs 33:32

7M ago33:32

33:32

This week’s podcast is sponsored by Vetter. On this week’s episode, we have a conversation with Steve Worland, CEO of eFFECTOR Therapeutics. eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs (selective translation regulation inhibitors). eFFECTOR’s STRI product ca…

1
Beyond Biotech podcast 62 – cytokine-based drugs 33:42

8M ago33:42

33:42

As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like in…

1
Beyond Biotech podcast 61 - Blood Cancer Awareness Month 24:44

8M ago24:44

24:44

On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed's CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to tackle blood cancers. One of the main challenges in treating blood cancers is the limited options for therapeutic intervention. Treatment relies primarily on chemo…

1
Beyond Biotech podcast 60 – The cost of research 33:45

8M ago33:45

33:45

On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology. Costs and Causes of Onco…

1
Beyond Biotech podcast 59 – World Lung Cancer Day 19:11

8M ago19:11

19:11

Since its inception in 2012, World Lung Cancer Day has been observed every year on August 1 in order to raise awareness of lung cancer issues and magnify the need for more lung cancer research funding. Around a quarter of a million people in the US alone will be diagnosed with some form of lung cancer in 2023. And more than 125,000 people in the US…

1
Beyond Biotech podcast 58: Pepteins 19:56

9M ago19:56

19:56

To learn about pepteins, we had a conversation with Christian Schwarz, CEO and co-founder of Numaferm. Numaferm is a German biotech company, specializing in the production of pepteins, which are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex p…

1
Beyond Biotech 57: Group B Strep 30:51

9M ago30:51

30:51

2:02 Labiotech.eu news 2:51 MinervaX To recognize International Group B Strep Awareness Month in July, we had a conversation with MinervaX CEO, Per Fischer. MinervaX is a privately-held Danish biotechnology company developing a novel prophylactic vaccine against Group B streptococcus (GBS), with two phase II clinical trials ongoing in pregnant wome…

1
Beyond Biotech podcast 56: BaseLaunch 35:31

9M ago35:31

35:31

2;00 Labiotech news 3:36 BaseLaunch In today's episode, we have a conversation with Stephan Emmerth, director business development and operations at biotech startup incubator BaseLaunch, and Sai Reddy, an entrepreneur well versed in the highs and lows of the biotech startup journey. The discussion includes BaseLaunch’s approach to empowering early-…

1
Beyond Biotech podcast 55: Inflammasomes 33:10

9M ago33:10

33:10

1:54 Labiotech news 3:48 NodThera This week, we’re talking about inflammasome inhibitors with Alan Watt, CEO of NodThera. The company recently announced it is the first to show a reduction in neuroinflammation with an inflammasome inhibitor. NodThera announced positive initial data from four subjects in the elderly volunteer stage of its phase Ib…

1
Beyond Biotech 54 27:48

10M ago27:48

27:48

1:24 Labiotech news 3:45 TolerogenixX TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the…

1
Beyond Biotech podcast 53: Antibody-drug conjugates 26:35

10M ago26:35

26:35

2:55 Labiotech news 4:27 Mablink Bioscience On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cance…

1
Beyond Biotech podcast 52: Antiphospholipid syndrome 43:46

10M ago43:46

43:46

2:38 Labiotech news 4:23 APSFA 20:59 University of Michigan June is Antiphospholipid Syndrome (APS) Awareness Month. APS is a rare autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. There are two known forms. APS may occur in people wi…

1
Beyond Biotech podcast 51 54:38

10M ago54:38

54:38

1:13 Labiotech news 3:09 Lund Spring Symposium 27:36 Sapient Sapient Sapient is an end-to-end biomarker discovery organization dedicated to accelerating the mapping of circulating chemistries in humans through rapid, large-scale small molecule biomarker profiling. Its platform combines next-generation mass spectrometry technologies capable of assay…

1
Beyond Biotech podcast 50: cell and gene therapy 1:09:01

10M ago1:09:01

1:09:01

2:45 Labiotech news 4:58 Orgenesis 22:35 CellProthera 38:22 Terumo Blood and Cell Technologies 52:02 BioSenic The International Society for Cell & Gene Therapy (ISCT), the global society of more than 3,000 members dedicated to the translation of cell and gene therapies (CGT) into safe and effective treatments to improve patient lives, recently host…

1
Beyond Biotech podcast 49 25:17

11M ago25:17

25:17

1:24 Labiotech news 3:40 BC Platforms A conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma. The acquisition expands BCP’s global service offering for accelerating the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional se…

1
Beyond Biotech podcast 48 26:04

11M ago26:04

26:04

1:18 Labiotech news 3:37 BioInvent BioInvent International AB, a Swedish biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, recently announced positive pha…

1
Beyond Biotech podcast 47 25:42

11M ago25:42

25:42

1:33 Labiotech news 3:31 Daiichi Sankyo/AstraZeneca The companies Daiichi Sankyo and AstraZeneca have worked together for several years. This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca. On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Seni…

1
Beyond Biotech podcast 46: International Clinical Trials Day 46:42

11M ago46:42

46:42

4:26 Labiotech news 6:36 Medidata 21:43 Bill & Melinda Gates Research Institute This week’s podcast is sponsored by Jubilant Biosys. May 20 is International Clinical Trials Day. ECRIN, the European Clinical Research Infrastructure Network, is a not-for-profit organization that supports the conduct of multinational clinical trials in Europe. Based i…

1
Beyond Biotech podcast 45: International MPS Awareness Day 26:33

12M ago26:33

26:33

This week’s podcast is sponsored by Quantoom. International MPS Awareness Day May is the big month when it comes to awareness - there are almost 100 awareness months, weeks, and days being marked. Some of these are well known conditions. Others, however, are less prominent. International MPS (mucopolysaccharidosis) Awareness Day takes place on May …

1
Beyond Biotech podcast 44 35:22

12M ago35:22

35:22

3:32 Labiotech news 5:33 Lupus interview This week’s podcast is sponsored by Lonza. May is Lupus Awareness Month, and to talk about lupus with us this week on the podcast are Katherine Tran, senior global market development & marketing manager of the proteomics division at SCIEX, and Allan Stensballe, associate professor, Department of Health Scien…

1
Beyond Biotech podcast 43 31:46

12M ago31:46

31:46

2:13 Labiotech news 5:17 bit.bio This week’s podcast is sponsored by Scientist.com. The mainstream news in the past couple of months has picked up on artificial intelligence (AI). Not so much its uses, more the potential for conflict and fears over AI developing too quickly, or ‘taking over humanity.’ Debates have sprung up around deepfakes, ChatGP…

1
Beyond Biotech podcast 42 32:35

1y ago32:35

32:35

2:05 Labiotech news 3:32 MEET2WIN 9:38 Lund Spring Symposium 19:31 Merck This week, we’re talking about the upcoming Lund Spring Symposium with Claes Wahlestedt, Leonard M. Miller professor and director of the Center for Therapeutic Innovation (CTI) and associate dean for therapeutic innovation at the University of Miami Miller School of Medicine; …

Подкасти, які варто послухати

Подкасти на тему Labiotech

Подкасти, які варто послухати

Короткий довідник